CD4 and AIDS: The START Trial showed that the immediate initiation of antiretroviral therapy among previously untreated adults living with HIV with a CD4 count >500 cells/mm3 was superior to initiation that was delayed until the CD4 count declined to 350 cells/mm3, based on a composite outcome including serious AIDS-related and non-AIDS related events [10].